The popularity of Viagra initially fueled a surge for pharma, however recent shifts present a murky outlook for investors. Off-patent competitors are reducing earnings, and continued litigation add more complexity to the equation. While specific companies may still see gains from related products, the broader trajectory suggests a cautious approach